Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;37(4):372-376.
doi: 10.1097/CCO.0000000000001147. Epub 2025 Apr 23.

Medical treatment of angiosarcomas

Armelle Dufresne  1 , Margaux Dupont, Mehdi Brahmi
Affiliations
Review

Medical treatment of angiosarcomas

Armelle Dufresne et al. Curr Opin Oncol. .

Abstract

Purpose of review: Medical treatment of angiosarcomas is based on chemotherapy and tyrosine kinase inhibitors with limited efficacy. Immune therapy represents an exciting new therapeutic opportunity in this indication.

Recent findings: Several clinicals trials, randomized or not, have been recently released to better define the scope and efficacy of immune therapy in angiosarcoma.

Summary: Angiosarcoma is a rare and malignant aggressive soft tissue sarcoma with a wide diversity of presentation in terms of location, aetiology, biology. Medical treatment may be considered as neo adjuvant treatment for locally advanced disease or as palliative treatment in case of metastatic spreading. Doxorubicin and paclitaxel are the two regimens with highest level of evidence of efficacy. Other chemotherapy like gemcitabine or antiangiogenic tyrosine kinase inhibitors may also be efficient. Immune therapy represents an exciting new opportunity under assessment, the selection of patients likely to benefit from this strategy according to clinical or biological criteria remains to be defined. The access to innovative therapy for angiosarcoma is limited by the rarity and heterogeneity of the disease.

Keywords: angiosarcoma; anti angiogenic tyrosine kinase inhibitors; chemotherapy; immune therapy; medical treatment.

PubMed Disclaimer

References

    1. Young RJ, Natukunda A, Litière S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 19902014; 50:3178–3186.
    1. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26:5269–5274.
    1. Selby LV, Clark E, Chen JL, et al. Use of neoadjuvant paclitaxel in breast angiosarcoma—impact on surgical resection and response rates. J Surg Oncol 2024; 130:579–585.
    1. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012; 118:3330–3336.
    1. Constantinidou A, Sauve N, Stacchiotti S, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open 2020; 5:e000787.

MeSH terms

Substances